Revance Therapeutics gains after Teoxane's buyout proposal

Revance Therapeutics

06/01/2025 14:58

** Shares of anti-wrinkle injection maker Revance
Therapeutics  RVNC.O  gain 15.7% to $3.57
    ** Privately held Swiss medical aesthetics company Teoxane
proposed to acquire RVNC for $3.60 per share in cash
    ** The proposal implies a 16% premium over the
$3.10-per-share price agreement with Crown Laboratories
announced last month
    ** RVNC declined to comment
    ** Teoxane beneficially owns 6.2% of the outstanding shares
of common stock of RVNC
    ** RVNC stock fell ~65% in 2024

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))